Sign inJoin waitlistJoin the waitlist

David Warshal

Head, Division of Gynecologic Oncology · Cooper Medical School of Rowan University/Cooper University Hospital

Credentials: · · · · · ·

History

Division of Gynecologic Oncology · Cooper Medical School of Rowan University/Cooper University Hospital
Present
Gynecologic Cancer Center · Cooper Medical School of Rowan University/Cooper University Hospital
Present

University of Rochester
1993–1996
Obstetrics and Gynecology
1989–1993
Penn State College of Medicine
1982–1986

Research

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)
Journal of Clinical Oncology · 2020 · 288 citations
Prevalence and predictors of psychological distress among women with ovarian cancer
Journal of Clinical Oncology · 2004 · 139 citations
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study
Gynecologic Oncology · 2003 · 118 citations

Matthew Powell
7 papers
PD
Paul DiSilvestro
7 papers
David Miller
6 papers
Krishnansu Tewari
6 papers
Mark Shahin
6 papers
Giuseppe Del Priore
5 papers · 2 as a fellow
Angeles Secord
4 papers
Brent DuBeshter
4 papers
Cynthia Angel
4 papers · 1 as a fellow
David Mutch
4 papers
CK
Chelsea Katz
3 papers · 3 as a resident
James Aikins
3 papers

Clinical trials

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Site PI · Recruiting
NRG Oncology
2020–2047
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Site PI · Unknown · Phase 3
Gynecologic Oncology Group
2012